Patents by Inventor Wolfgang Fraunhofer

Wolfgang Fraunhofer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140141007
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • Publication number: 20140141008
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • Publication number: 20140017256
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 16, 2014
    Applicant: ABBVIE INC.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20130156760
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: February 22, 2013
    Publication date: June 20, 2013
    Applicant: ABBVIE, INC.
    Inventors: Wolfgang FRAUNHOFER, Annika BARTL, Hans-juergen KRAUSE, Markus TSCHOEPE, Katharina KALETA
  • Patent number: 8436149
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: May 7, 2013
    Assignee: AbbVie Biotechnology Ltd
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Patent number: 8420081
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: April 16, 2013
    Assignee: AbbVie, Inc.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Patent number: 8404819
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: March 26, 2013
    Assignee: AbbVie Inc.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20120263731
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: November 11, 2011
    Publication date: October 18, 2012
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: Wolfgang Fraunhofer, Laura Redden, Susan K. Paulson, Tong Zhu, Michael Neu, Markus Tschoepe, Carsten Weber, Martin Gastens, Alexander Feick
  • Publication number: 20120251550
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: September 2, 2011
    Publication date: October 4, 2012
    Applicant: Abbott Biotechnology Ltd.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20120177704
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Application
    Filed: February 14, 2012
    Publication date: July 12, 2012
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Patent number: 8168760
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: May 1, 2012
    Assignee: Abbott Laboratories
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20110256135
    Abstract: The present invention relates to stable compositions of anti-NGF antibodies, and antigen-binding fragments thereof, and their uses in the prevention and/or treatment of various diseases and disorders in which NGF activity is detrimental, e.g., pain disorders.
    Type: Application
    Filed: March 16, 2011
    Publication date: October 20, 2011
    Inventors: Wolfgang FRAUNHOFER, Ravi Chari, Vineet Kumar, Rainer Saedler, Michael Siedler, William B. Stine, Carsten Weber
  • Patent number: 8034906
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: October 11, 2011
    Assignee: Abbott Biotechnology Ltd.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20100278822
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: May 3, 2010
    Publication date: November 4, 2010
    Applicant: ABBOTT BIOTECHNOLOGY, LTD.
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • Publication number: 20100172862
    Abstract: The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of IL-12/IL-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation.
    Type: Application
    Filed: November 24, 2009
    Publication date: July 8, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Ivan R. Correia, Czeslaw H. Radziejewski, Wolfgang Fraunhofer, Nicholas W. Warne, Angela Kantor
  • Publication number: 20100034823
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: October 25, 2007
    Publication date: February 11, 2010
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20090291062
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: November 28, 2008
    Publication date: November 26, 2009
    Inventors: Wolfgang FRAUNHOFER, Annika Bartl, Hans-juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Publication number: 20090148513
    Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: August 8, 2008
    Publication date: June 11, 2009
    Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20080292642
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Application
    Filed: March 27, 2008
    Publication date: November 27, 2008
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk